Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 11/20 | 0.34 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.34 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266478 | 0.90 | CHRNA7 (0.35) | CHRNA7POLBGNRHRKCNJ6KCNJ5 | |
| Ammonia Solution, Strong SCHEMBL2958892 | 0.90 | CHRNA7 (0.35) | CHRNA7POLBGNRHRKCNJ6KCNJ5 | |
| SCHEMBL2952198 | 0.90 | CSF1R (0.39) | CHRNA7KCNJ6KCNJ5KCNJ3CSF1R | |
| Lithium Ion SCHEMBL1266477 | 0.89 | CHRNA7 (0.35) | CHRNA7POLBGNRHRKCNJ6KCNJ5 | |
| SCHEMBL1267006 | 0.87 | DHODH (0.44) | POLB | |
| SCHEMBL1266727 | 0.85 | DHODH (0.34) | CHRNA7KCNJ6KCNJ5KCNJ3MAPK8 | |
| SCHEMBL1267284 | 0.84 | ADORA2B (0.35) | CHRNA7KCNJ6KCNJ5KCNJ3CSF1R | |
| SCHEMBL5668001 | 0.83 | KHK (0.34) | CHRNA7KCNJ6KCNJ5KCNJ3LMNA | |
| SCHEMBL1266952 | 0.83 | MET (0.39) | — | |
| SCHEMBL1266352 | 0.83 | MET (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | claimed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | CHRNA7 1817/4885POLB 1601/4885GNRHR 1624/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | CHRNA7 2079/4885POLB 1672/4885GNRHR 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.